Innova Captab Q4 FY26 Earnings Analysis
Published 6 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹5.4K Cr
Price
₹945
Market Cap
₹5.4K Cr
P/E Ratio
38.5
Earnings Summary
- Overall business growth targeted at 20%+ year-on-year (Vinay Lohariwala, Q3 FY26 call). - Jammu facility expected to drive 20%+ growth for the next 2-3 years with revenues ramping up from Rs. - Innova Captab projects a sustained overall growth of 20%+ year-on-year at the organization level, driven significantly by ramp-up at the Jammu facility for the next 2-3 years. - Jammu facility revenues are expected to grow from Rs.
📊 Revenue & Sales Performance
- Overall business growth targeted at 20%+ year-on-year (Vinay Lohariwala, Q3 FY26 call). - Jammu facility expected to drive 20%+ growth for the next 2-3 years with revenues ramping up from Rs. 89 crores in Q3 FY26 towards a potential Rs. 1,400 crores at optimum capacity (Lokesh Bhasin, Vinay Lohariwala). - Jammu offers significant room for scaling beyond FY28-29, with future growth strategies in development (Vinay Lohariwala). - Branded generics projected to sustain growth around 20%+ annually over the next 2-3 years, supported by domestic and international expansion (Vinay Lohariwala, Lokesh Bhasin). - Volume growth in CDMO ex-Jammu estimated at 6-10% year-on-year; price growth assumed stable (Lokesh Bhasin, Vinay Lohariwala). - Export share growing steadily, with exports forming ~35% revenue mix in Q3 FY26 and aiming for stable 35-65% export-domestic mix (Lokesh Bhasin, Vinay Lohariwala).
📈 Profitability & Margins
- Innova Captab projects a sustained overall growth of 20%+ year-on-year at the organization level, driven significantly by ramp-up at the Jammu facility for the next 2-3 years. - Jammu facility revenues are expected to grow from Rs. 280-290 crores in FY26, with optimism to slightly surpass this, contributing positively to EBITDA and PAT margins next year. - Branded generics segment growth is targeted at 20%+ annually, supported by both domestic and international market expansions. - EBITDA margins are expected to remain around 15-17%, with potential margin improvement from Jammu contribution; however, future growth strategies may exert some pressure on margins. - Continued focus on operational efficiency, geographic expansion, and product pipeline development aims to sustain profitability amid volume and sales mix changes. - No firm guidance on full-year FY26 revenue growth beyond existing quarterly trends was provided.
🏗️ Capital Expenditure Plans
- Innova Captab is focused on ramping up the Jammu facility, which started commercial production in January 2025 and is expected to drive 20%+ overall business growth for the next 2-3 years. - Jammu facility has potential revenue capacity of Rs. 1,400+ crores at 65-75% utilization. - The company is actively working on future growth strategies beyond FY28-29 to identify new growth engines and will inform the market once plans are finalized. - Current operations at Jammu are nearing EBITDA breakeven, with positive contributions expected in FY27. - Existing plants at Baddi, Dehradun, and Taloja operate at 55-60% capacity, implying potential for 15-25% growth without immediate expansion. - No specific new capex announced, but strategic steps are underway for long-term growth beyond Jammu's ramp-up.
💰 Fundraising & Capital Structure
- The transcript does not mention any current or planned fundraising through debt or equity. - Management highlights focus on organic growth, ramping up existing facilities (like Jammu), and pursuing future growth strategies. - There is acknowledgment of potential P&L pressures due to future growth strategies but no specific discussion of raising funds. - The company prefers to communicate any major strategic moves, including fundraising, to the market once plans are finalized. - No explicit guidance or announcement regarding equity or debt issuance was provided during this call.
📋 Order Book & Pipeline
The transcript provided does not explicitly mention details about the current or expected order book or pending orders for Innova Captab Limited. However, relevant insights related to business momentum and growth include: - The Jammu facility is ramping up smoothly with commercial operations underway and marquee CDMO partners. - Innova Captab reported robust 42.3% YoY revenue growth in Q3 FY26, indicating strong demand. - The CDMO business delivered 29% YoY growth, powered by partnerships and new client wins. - The company is optimistic about further growth, including 20%+ growth projections at the entity level. - Multiple growth levers are active such as capacity expansion and geographical diversification supporting sustained revenue acceleration. - New GMP certifications coupled with audits from marquee customers support demand visibility. No specific quantified order book or pending orders details were disclosed during the call.
Key Metrics
Frequently Asked Questions
What were Innova Captab Q4 FY26 results?
- Overall business growth targeted at 20%+ year-on-year (Vinay Lohariwala, Q3 FY26 call). - Jammu facility expected to drive 20%+ growth for the next 2-3 years with revenues ramping up from Rs. - Innova Captab projects a sustained overall growth of 20%+ year-on-year at the organization level, driven significantly by ramp-up at the Jammu facility for the next 2-3 years. - Jammu facility revenues are expected to grow from Rs.
What is Innova Captab share price analysis?
Innova Captab currently shows a neutral. The stock trades at a P/E of 38.5 with a market cap of ₹5,408. Investors should review the full earnings analysis for detailed insights.
Is Innova Captab planning capital expenditure?
- Innova Captab is focused on ramping up the Jammu facility, which started commercial production in January 2025 and is expected to drive 20%+ overall business growth for the next 2-3 years. - Jammu facility has potential revenue capacity of Rs.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
